Glioma is a major histological subtype of primary malignant brain tumors in Taiwan, with distinct epidemiological, clinical, and pathological features comparing to the other common cancer diseases. The disease rarely appears with metastatic disease at diagnosis, and with the most malignant subtype, glioblastoma, occurs with preference in mid- to old-age. For decades, primary malignant brain tumors has been known as one of the most desperate disease without successful improvement regarding of the treatment. Surgical resection is the principle for the primary treatment of gliomas. Chemotherapy and radiotherapy are often applied to patients for adjuvant therapy of surgery to pursue the treatment effect. Disappointedly, vast majority of the patients would eventually develop disease recurrence, leaving only limited choice for salvage treatment thereafter. The prognosis of these patients remains desperate, and thus a better understanding of this deadly disease is crucial for finding better therapeutic strategies for these patients.
Eligibility
Sex
ALL
Min age
20 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Pathological confirmation or suggestion of adult-type diffuse gliomas A. Diagnosis includes glioblastoma, astrocytoma, oligodendrocytoma that is listed in ATDG category per WHO criteria.
B. Gliomas that are preferred as ATDGs from pathological and clinical views, but not given for confirmed diagnosis.
2. Willingness to provide archival or newly obtained tumor tissues for current study proposal.
3. Age equal or more than 20 years old (inform consent).
4. Life expectancy more than 3 months.
5. Patients fully understand the protocol with the willingness to have regular follow-up.
6. Additional criteria for individual arms A. \[Arm 1\] Within 2 months after surgery for primary tumor. B. \[Arm 2\] Total resection of primary tumors with tissue samples available for test.
C. \[Arm 3\] (1) Total resection of primary tumors with the paired primary and recurrent tissue samples available for test. (2) IDH test suggesting wild-type.
Exclusion Criteria:
1. Gliomas diagnosed or preferred as other categories than ATDGs, such as pediatric-type diffuse gliomas, circumscribed astrocytic gliomas, and others.
2. Inability to cooperate by providing a complete medical history.
3. Patients disagree to provide archived tumor samples.
4. Undesirable compliance.
5. Having a known additional malignancy that is progressing or has required active treatment within the past 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., cervical carcinoma in situ) that have undergone potentially curative therapy are not excluded.
Primary outcome measure(s)
To evaluate the genetic profiles in brain tumor patients in Taiwan. — 5 years ACTonco+ACTFusion Biospecimen Retention: Samples With DNA One H\&E staining slide, and 15-20 tissue slides (5 um thickness) for cancer panel.
Details of Tests/Collaborative Test Unit:
Testing will take place in a certified precision medicine laboratory.
Non-tumor Sample (Blood): Seven(7)ml of cell free DNA and Eight (8) ml of blood in EDTA tube will be collected from the participant
Trial sites (8)
Facility
City
Region
Status
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City
Taiwan
Recruiting
Shuang Ho Hospital
New Taipei City
Taiwan
Recruiting
China Medical University Hospital
Taichung
Taiwan
Recruiting
Taichung Veterans General Hospital
Taichung
Taiwan
Recruiting
National Cheng Kung University Hospital
Tainan
Taiwan
Recruiting
National Taiwan University Hospital
Taipei
Taiwan
Recruiting
Taipei Medical University -Ministry of Health and Welfare Shuang-Ho Hospital
Taipei
Taiwan
Recruiting
CHANG GUNG MEMORIAL HOSPITAL, Linkou
Taoyuan
Taiwan
Recruiting
More National Health Research Institutes, Taiwan trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.